Syndax Announces Positive Data for Revumenib in Patients with …
Dec 11, 2023 · The Company announced data from the AUGMENT-102 trial of revumenib in combination with fludarabine/cytarabine in a predominantly pediatric relapsed/refractory mNPM1 (n=1), NUP98r (n=1) and KMT2Ar (n=13) AML population.
Syndax Announces Positive Pivotal Topline Results from Relapsed …
2 days ago · Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the ...
Syndax Presents Updated Positive Data from BEAT AML and …
Jun 14, 2024 · - Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML -
Syndax’s revumenib meets primary results in AML trial - Yahoo …
2 days ago · Syndax narrows FY24 CapEx view to $245M-$250M from $240M-$260M. Syndax to present new data on revumenib in leukemia. Syndax (SNDX) announced positive topline results from the relapsed or ...
Syndax Announces U.S. FDA Breakthrough Therapy Designation …
Dec 5, 2022 · Revumenib is a potent, selective, small molecule inhibitor of the menin-MLL binding interaction that is being developed for the treatment of KMT2A rearranged, also known as mixed lineage...
Syndax Announces Positive Pivotal Topline Results from Relapsed …
3 days ago · "We are thrilled to report positive pivotal data in R/R mNPM1 AML patients treated with revumenib, which has shown compelling and notably consistent results across treatment settings for both mNPM1 AML and KMT2A-rearranged acute leukemias," said Michael A. Metzger, Chief Executive Officer of Syndax. "With the anticipated FDA approval of ...
Syndax's Revumenib Trial Reports Positive Data In …
2 days ago · Looking ahead, Syndax expects to receive FDA approval for Revumenib for the treatment of relapsed or refractory KMT2Ar acute leukemias in the fourth quarter of 2024.
Syndax Announces Positive Data for Revumenib in Patients with …
Dec 11, 2023 · The new combination data collectively highlight revumenib's potential to safely combine with current standard of care agents across the acute leukemia treatment landscape, and support expansion...
Syndax Announces Positive Updated Data from Phase 1 Portion …
Dec 11, 2022 · AUGMENT-101 is a Phase 1/2 open-label trial designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of orally administered revumenib. The Phase 1 dose escalation portion of AUGMENT-101 was separated into two cohorts based on concomitant treatment with a strong CYP3A4 inhibitor.
Syndax Announces Revumenib Abstracts to Be Presented at the …
Nov 5, 2024 · The FDA has granted Priority Review for the New Drug Application (NDA) for revumenib for the treatment of adult and pediatric patients with relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar...
- Some results have been removed